Since the market approval of recombinant human insulin as a drug for diabetes treatment in 1982, many recombinant DNA pharmaceutical products including TNF‐alpha blockers have been developed. In general, these products have relatively lower incident of adverse events and high efficacy rates with their targeting properties. As approaching the expiration of patents for the first group of the originator bioproducts, developing “biosimilar” products to be a first provider in the market has been an issue amongst pharmaceutical companies. However, due to large and complex molecular structure of biologics, manufacturing processes including types of cell lines and media are highly influencing on the product quality. Even when a minuscule modification is applied in the manufacturing process of a biological product, it is hardly assure that the product is the same as the one made through previous process. Therefore, the comparability to original products is an essential component in biosimilar product development. Comparability is not only an issue of quality but issues carefully treated in safety and efficacy evaluation. In this presentation, we will share the experience gained through the biosimilar development and discuss about potential problems in depth.
저자
Kyoo Jung SHIM [ Hanwha Biobusiness Unit, Hanwah Chemical, Korea ]
한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
설립연도
1984
분야
공학>생물공학
소개
이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다
1. 생물공학 분야의 발전을 위한 연구 협력
2. 생물공학의 실용화를 촉진시키기 위한 산학 협동
3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최
4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간
5. 생물공학 발전을 위한 정책 건의
6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동